Abstract:Background and ObjectiveThe association between the CYP3A4*1B single nucleotide polymorphism (SNP) and tacrolimus pharmacokinetics in different studies is controversial. Therefore, a meta-analysis was employed to evaluate the correlation between the CYP3A4*1B genetic polymorphism and tacrolimus pharmacokinetics at different post-transplantation times in adult renal transplant recipients.MethodsStudies evaluating the CYP3A4*1B genetic polymorphism and tacrolimus pharmacokinetics were retrieved through a systematical search of Embase, PubMed, the Cochrane Library, ClinicalTrials.gov and three Chinese literature databases (up to Sept. 2014). The pharmacokinetic parameters (weight-adjusted tacrolimus daily dose and tacrolimus trough concentration/weight-adjusted tacrolimus daily dose ratio) were extracted, and the meta-analysis was performed using Stata 12.1.ResultsSeven studies (involving 1182 adult renal transplant recipients) were included in this meta-analysis. For the weight-adjusted tacrolimus daily dose, in all included renal transplant recipients (European & Indian populations), CYP3A4*1/*1 recipients required a significantly lower weight-adjusted tacrolimus daily dose than did CYP3A4* 1B carriers at 7 days (WMD -0.048; 95% CI -0.083 similar to -0.014), 6 months (WMD -0.058; 95% CI -0.081 similar to -0.036) and 12 months (WMD -0.061; 95% CI -0.096 similar to -0.027) post-transplantation. In light of the heterogeneity, the analysis was repeated after removing the only study in an Indian population, and CYP3A4*1/*1 European recipients (mostly Caucasian) required a lower weight-adjusted tacrolimus daily dose within the first year post-transplantation. The tacrolimus trough concentration/weight-adjusted tacrolimus daily dose ratio (C-0/Dose ratio) was significantly higher in CYP3A4*1/*1 recipients than in CYP3A4*1B carriers at 6 months (WMD 52.588; 95% CI 22.387 similar to 82.789) and 12 months (WMD 62.219; 95% CI 14.218 similar to 110.221) post-transplantation. When the only study in an Indian population was removed to examine European recipients (mostly Caucasian), the significant difference persisted at 1 month, 6 months and 12 months post-transplantation.ConclusionBased on our meta-analysis, the CYP3A4*1B genetic polymorphism affects tacrolimus dose requirements and tacrolimus trough concentration/weight-adjusted tacrolimus daily dose ratio within the first year post-transplantation in adult renal transplant recipients, especially in European recipients (mostly Caucasian).

The Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients

Effect of cytochrome P450 3A5 (CYP3A5) genotype on tacrolimus dose requirement in renal transplant patients

Influence Of Cyp3a5 And Mdr1 Polymorphisms On Tacrolimus Concentration In The Early Stage After Renal Transplantation

Influence of CYP 3A5*3 genetic polymorphism on tacrolimus pharmacokinetics in renal transplant recipients

Influence of CYP3A5 polymorphism on tacrolimus blood concentrations in renal transplant patients

ABCB1 Haplotype Influences the Sirolimus Dose Requirements in Chinese Renal Transplant Recipients.

CYP 3A 5 and MDR1 Gene Polymorphisms is Associated with Pharmacokinetic Variation of Tacrolimus in Renal Transplant Patients

Effect of CYP3A5 and MDR1 Gene Polymorphism on Concentration/Dose Ratios of Tacrolimus in Chinese Liver Transplant Patients

Effect of CYP3A5 polymorphism on the concentration /dose ratio of tacrolimus in liver transplant recipients

Association Of Cyp3a4*18b Polymorphisms With The Pharmacokinetics Of Tacrolimus In Chinese Renal Transplant Recipients

CYP3A5 Rather Than MDR1 Gene Polymorphism of Recipient is Related to Tacrolimus Individual Dose Requirement in Chinese Liver Transplant Patients

Effects of CPY3A5 Genetic Polymorphisms on the Pharmacokinetics of Extendedrelease and Immediate-release Tacrolimus Formulations in Renal Transplant Recipients: A Systematic Review and Meta-analysis

Systematic review on effects of CYP3A4*1G genetic polymorphism on daily dose of tacrolimus and drug concentration in renal transplant recipients

Gene Polymorphisms of CYP 3AP1 and MDR1 Associated with the Interindividual Variability of Tacrolimus Concentration

IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients

Combined Effect of Donor Cytochrome P450 3A Family Polypeptide 5 and Recipient Cytochrome P450 3A Family Polypeptide 4 Polymorphisms on the Individual Dosage Regimen of Tacrolimus in Chinese Liver Transplant Patients

Effects Of The Cyp3a4*1b Genetic Polymorphism On The Pharmacokinetics Of Tacrolimus In Adult Renal Transplant Recipients: A Meta-Analysis

Influence Of Cyp3a5 Gene Polymorphisms Of Donor Rather Than Recipient To Tacrolimus Individual Dose Requirement In Liver Transplantation

Association of CYP3A5 and C5 Polymorphisms with the Individual Dosage Regimen of Tacrolimus in Chinese Liver Transplantation Recipients During the Early Post-Transplantation Period

CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation.

Association of Hemoglobin Levels, CYP3A5, and NR1I3 Gene Polymorphisms with Tacrolimus Pharmacokinetics in Liver Transplant Patients